Hepatocellular Cancer Completed Phase 1 / 2 Trials for Emibetuzumab (DB11849)

Also known as: Cancer, Hepatocellular

IndicationStatusPhase
DBCOND0037277 (Hepatocellular Cancer)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02082210A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced CancerTreatment